Preclinical markers studies Parkinson disease development reliable preclinical detection procedures idiopathic Parkinson disease fundamental advance establishment cause natural history prevention neurodegenerative disorder usefulness preclinical markers efforts etiology development disorder direct measures dopamine production indirect measures metabolic changes comorbidity first decades life invasive expensive sophisticated simple cheap overview criteria evaluation utility specific markers assessment importance early markers future research 